ClinicalTrials.gg
RecruitingNCT05668637IntelliLungUpdated Apr 21, 2026

Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support

An observational study in Invasive Mechanical Ventilation, sponsored by Technische Universität Dresden. Recruiting at 8 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Technische Universität Dresden · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
318,542
Ages
18 Years and older
Sex
All
01

Study summary

Invasive mechanical ventilation is one of the most important and life-saving therapies in the intensive care unit (ICU). In most severe cases, extracorporeal lung support is initiated when mechanical ventilation is insufficient. However, mechanical ventilation is recognised as potentially harmful, because inappropriate mechanical ventilation settings in ICU patients are associated with organ damage, contributing to disease burden. Studies revealed that mechanical ventilation is often not provided adequately despite clear evidence and guidelines. Variables at the ventilator and extracorporeal lung support device can be set automatically using optimization functions and clinical recommendations, but the handling of experts may still deviate from those settings depending upon the clinical characteristics of individual patients. Artificial intelligence can be used to learn from those deviations as well as the patient's condition in an attempt to improve the combination of settings and accomplish lung support with reduced risk of damage.

02

Conditions studied

  • Invasive Mechanical Ventilation

Keywords

  • Mechanical ventilation
  • ventilator-induced lung injury
  • ARDS
  • artificial intelligence
03

In context

Ventilator-Induced Lung Injury

122 studies on the registry are indexed under Ventilator-Induced Lung Injury; 40 are open to participants now.

This study's planned enrollment of 318,542 is above the median of 60 across 42 observational studies indexed under Ventilator-Induced Lung Injury.

Browse Ventilator-Induced Lung Injury studies →

Lead sponsor

Technische Universität Dresden is the lead sponsor of 247 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Intensive care patients receiving invasive mechanical ventilation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are 18 years or older and receive invasive mechanical ventilation for > 4 hours

Exclusion criteria

Exclusion Criteria:

  • Patients receiving one-lung ventilation
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
318,542 participants (estimated)
Patient registry
No

Interventions

  • OtherArtificial Intelligence-based Decision support

    Decision support to optimise invasive mechanical ventilation settings

06

What researchers measure

Primary outcomes

  1. Relative time of same device settings of the health care provider and the IntelliLung algorithm

    Time frame: From date of intubation to date of extubation or date of discharge, which ever came first, assessed up to 12 month

07

Study locations

2 of 8 sites recruiting
  • Cleveland Clinic Foundation, Cleveland, USA
    Cleveland, Ohio 44195, United States
    Recruiting
  • University Hospital Carl Gustav Carus Dresden
    Dresden, Germany
    Recruiting
  • Institut Fur Angewandte Informatik (Infai) Ev
    Leipzig, Germany
    Active, not recruiting

    Not enrolling at this site.

  • Institut Mihajlo Pupin
    Belgrade, Serbia
    Active, not recruiting

    Not enrolling at this site.

  • Better Care Sl
    Sabadell, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Fundacio Parc Tauli
    Sabadell, Spain
    Completed

    Not enrolling at this site.

  • Fundacion Publica Andaluza Progreso Y Salud
    Seville, Spain
    Active, not recruiting

    Not enrolling at this site.

  • Inselspital, Universitätsspital Bern
    Bern, Switzerland
    Completed

    Not enrolling at this site.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Sep 2026, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2022
First posted
Dec 30, 2022
StartActual
Jan 1, 2023
Primary completionEst.
Sep 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05668637
Responsible party
Sponsor
First posted
Dec 30, 2022
Start date
Jan 1, 2023
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Apr 21, 2026

Study contacts

Jakob Wittenstein, MD
Contact
jakob.wittenstein@ukdd.de
+49 351 458 19887
Thea Koch, PhD
Contact
thea.koch@ukdd.de
Jakob Wittenstein, MD
principal investigator · University Hospital Carl Gustav Carus at Technischen Universität Dresden, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion